Skip to main content

Bendamustine hydrochloride

Names

Treanda® Bendamustine hydrochloride Bendeka™

Indications and usage

Bendamustine hydrochloride is FDA approved to treat people who have:

  • Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.
  • Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. 

Side effects needing medical attention

Side effects needing medical attention

Low blood cell counts, infections, infusion reactions, anaphylaxis, tumor lysis syndrome, skin reactions, other cancers, leaking of bendamustine hydrochloride out of your vein and into your surrounding skin, fever, nausea, and vomiting.

The Leukemia & Lymphoma Society (LLS) is now Blood Cancer United. Learn more.